Lung Cancer Trials Ask AI to find trials
UnknownNot applicableNCT05669105
Official study title

Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research

Study summary

The study objective is to collect biospecimen samples (e.g., whole blood) from participants diagnosed with active lung cancer to investigate the immune response to develop treatments and therapies.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedSpecimen sample

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Nov 22, 2023 · Source: ClinicalTrials.gov

Is enrollment open?Unknown

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Sanguine Biosciences

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Sanguine Biosciences
Interventions being studied
Diagnostic Test: Specimen sample
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Participants willing and able to provide written informed consent
  • Participants are willing and able to provide appropriate photo identification
  • Participant's age 18 - 100 years old
  • Participants diagnosed with active non-small cell lung cancer (Adenocarcinoma or Squamous Cell only. All stages are acceptable.)
  • Participants must have associated tissue biomarker data (EFGR and MET mutations) in their medical records
Reasons someone may not be able to joinExclusion criteria
  • Participants who are pregnant or nursing
  • Participants with a known history of HIV, hepatitis, or other infectious diseases
  • Participants who have taken an investigational product in the last 30 days
  • Participants who have experienced excess blood loss, including blood donation defined as 250 mL in the last month or 500 mL in the previous two months
  • Participants currently enrolled in a clinical trial
  • Participants currently in remission

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Sanguine BiosciencesWaltham, Massachusetts

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 22, 2023. Always confirm current availability with the study team.

View original record ↗